Business
Preliminary Results for the year ended 31 Dec 2018
Preliminary Results for the year ended 31 Dec 2018.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 6825V Futura Medical PLC 10 April 2019 \n\n\n\n\n\n \n\n\n \n\n\n\n\nTHE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF REGULATION (EU) NO 596/2014 OF THE MAR. UPON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN \n \n 10 April 2019\n \n \nFutura Medical plc\n(\"Futura\" or \"the Company\")\n \nPreliminary Results for the year ended 31 December 2018\n \nSustained Progress made in 2018\n \nFutura Medical plc (AIM: FUM), the pharmaceutical company developing a portfolio of innovative products for sexual health and pain, based on its proprietary, transdermal DermaSys® drug delivery technology is pleased to announce its preliminary results for the year ended 31 December 2018.\n \nHighlights\n \nOperational highlights\n· Following an extensive strategic review which was announced in September 2018, Futura has focused on maximising value in its development pipeline and product portfolio addressing two large market categories, sexual health and pain. The lead priorities are MED2005, its innovative topical treatment for erectile dysfunction (ED), and its pain portfolio including TPR100, a topical non-steroidal anti-inflammatory drug. Futura's core objectives are to:\n− complete the devel...